Felis ISSN 2398-2950

Maropitant citrate

Synonym(s): Cerenia®

Contributor(s): Clive Elwood, Linda Horspool

Introduction

Name

  • Maropitant citrate.

Class of drug

  • Anti-emetic.
  • Neurokinin (NK1) receptor antagonist.

Description

Chemical name

  • (2S,3S)-2-benzhydryl-N-(5-tert-butyl-2-methoxybenzyl)quinuclidin-3-amine citrate monohydrate.

Molecular formula

  • C32H40N20C6H807H20

Molecular weight

  • 678.81

Physical properties

  • Peach-colored oval tablets (16, 24, 60 and 160 mg of maropitant as maropitant citrate per tablet).
  • Injectable solution (10 mg maropitant, 63 mg sulphobutylether-beta-cyclodextrin, 3.3 mg meta-cresol and water).

Storage requirements

  • Store at controlled room temperature (20-25°C; 68-77°F) with excursions between 15-30°C (59-86°F).
  • Use vial of injectable solution within 28 days of first vial puncture.

Uses

This article is available in full to registered subscribers

Sign up now to purchase a 30 day trial, or Login

Indications

  • Prevention of emesis   Vomiting  .
  • Prevention of emesis associated with motion sickness in dogs.

Administration

This article is available in full to registered subscribers

Sign up now to purchase a 30 day trial, or Login

Pharmocokinetics

This article is available in full to registered subscribers

Sign up now to purchase a 30 day trial, or Login

Precautions

This article is available in full to registered subscribers

Sign up now to purchase a 30 day trial, or Login

Interactions

with other drugs

  • Use with caution with other protein bound drugs. The concomitant use of Cerenia® with other protein bound drugs such as NSAIDs, cardiac, anticonvulsant and behavioral medications has not been evaluated.

Further Reading

Publications

Refereed papers

  • Recent references from PubMed.
  • Hickman M Aet al(2008)Safety, pharmacokinetics and use of the novel NK-1 receptor antagonist maropitant (Cerenia) for the prevention of emesis and motion sickness in cats. J Vet Pharmacol Ther31(3), 220-229PubMed.
  • Benchaoui H A, Siedek E M, de la Puente-Redondo V A, Tilt N, Rowan T G & Clemence R G (2007)Efficacy of maropitant for preventing vomiting associated with motion sickness in dogs.Vet Rec161, 444-447 PubMed.
  • Benchaoui H A, Cox S R, Schneider R P, Boucher J F & Clemence R G (2007)The pharmacokinetics of maropitant, a novel neurokinin type-1 receptor anatagonist, in dogs.J Vet Pharmacol Ther30(4), 336-344PubMed.
  • de la Puente-Redondo V A, Siedek E M, Benchaoui H A, Tilt N, Rowan T G & Clemence R G (2007)The anti-emetic efficacy of maropitant (Cerenia) in the treatment of ongoing emesis caused by a wide range of underlying clinical aetiologies in canine patients in Europe.JSAP48(2), 93-98 PubMed.
  • de la Puente-Redondo V A, Tilt N, Rowan T G & Clemence R G (2007)Efficacy of maropitant for treatment and prevention of emesis caused by intravenous infusion of cisplatin in dogs.Am JVet Res68(1), 48-56 PubMed.

Other sources of information


ADDED